Skip to main content
Erschienen in: International Journal of Clinical Oncology 5/2015

01.10.2015 | Original Article

Characteristics of neoplastic cardiac tamponade and prognosis after pericardiocentesis: a single-center study of 113 consecutive cancer patients

verfasst von: Tsugumi Takayama, Yuji Okura, Yoshinobu Okada, Keiichi Honma, Atsushi Nashimoto, Nobuaki Sato, Akira Yokoyama, Tohru Minamino

Erschienen in: International Journal of Clinical Oncology | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Neoplastic cardiac tamponade (NCT) is a life-threatening complication of cancer. The interval between cancer diagnosis and NCT onset and the prognosis after pericardiocentesis may differ according to cancer type.

Methods and results

We performed a retrospective study of 113 patients (54 % male) with NCT who underwent pericardiocentesis at Niigata Cancer Center Hospital between 1992 and 2013. Mean age at NCT was 61.2 years (range 15.9–94.8 years). The most common underlying cancers were lung cancer (59.2 %), breast cancer (21.2 %), lymphoma/leukemia (5.3 %), and gastric/esophageal cancer (5.3 %). The median time from cancer diagnosis to NCT onset was 9.0, 60.4, 5.6, and 8.0 months for lung cancer, breast cancer, lymphoma/leukemia, and gastric/esophageal cancer, respectively. Kaplan–Meier survival estimates were worse for breast cancer patients with NCT than for matched breast cancer patients without NCT (P < 0.0001). Median survival time after pericardiocentesis was 2.9, 4.2, 2.3, and 0.6 months for lung cancer, breast cancer, lymphoma/leukemia, and gastric/esophageal cancer, respectively; one-year survival after pericardiocentesis was 6.0, 16.7, 33.3, and 0 %, respectively.

Conclusions

The interval between cancer diagnosis and NCT onset, the impact of NCT on prognosis, and the prognosis after pericardiocentesis differed according to cancer type. Healthcare practitioners caring for patients with NCT should recognize the differences between cancer types and customize their care accordingly.
Literatur
3.
Zurück zum Zitat Vaitkus PT, Herrmann HC, LeWinter MM (1994) Treatment of malignant pericardial effusion. JAMA 272:59–64CrossRefPubMed Vaitkus PT, Herrmann HC, LeWinter MM (1994) Treatment of malignant pericardial effusion. JAMA 272:59–64CrossRefPubMed
4.
Zurück zum Zitat De Lima L (2007) International Association for Hospice and Palliative Care list of essential medicines for palliative care. Ann Oncol 18:395–399CrossRefPubMed De Lima L (2007) International Association for Hospice and Palliative Care list of essential medicines for palliative care. Ann Oncol 18:395–399CrossRefPubMed
5.
Zurück zum Zitat Ikematsu Y, Kloos JA (2012) Patients’ descriptions of dysphoria associated with cardiac tamponade. Heart Lung 41:264–270CrossRefPubMed Ikematsu Y, Kloos JA (2012) Patients’ descriptions of dysphoria associated with cardiac tamponade. Heart Lung 41:264–270CrossRefPubMed
6.
Zurück zum Zitat Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y et al (2004) Guidelines on the diagnosis and management of pericardial diseases executive summary; the task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J 25:587–610CrossRefPubMed Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y et al (2004) Guidelines on the diagnosis and management of pericardial diseases executive summary; the task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J 25:587–610CrossRefPubMed
7.
Zurück zum Zitat Singh S, Wann LS, Klopfenstein HS, Hartz A, Brooks HL (1986) Usefulness of right ventricular diastolic collapse in diagnosing cardiac tamponade and comparison to pulsus paradoxus. Am J Cardiol 57:652–656CrossRefPubMed Singh S, Wann LS, Klopfenstein HS, Hartz A, Brooks HL (1986) Usefulness of right ventricular diastolic collapse in diagnosing cardiac tamponade and comparison to pulsus paradoxus. Am J Cardiol 57:652–656CrossRefPubMed
8.
Zurück zum Zitat Kunitoh H, Tamura T, Shibata T, Imai M, Nishiwaki Y, Nishio M et al (2009) A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811). Br J Cancer 100:464–469PubMedCentralCrossRefPubMed Kunitoh H, Tamura T, Shibata T, Imai M, Nishiwaki Y, Nishio M et al (2009) A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811). Br J Cancer 100:464–469PubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Smith TJ, Temin S, Alesi ER, Abernethy AP, Balboni TA, Basch EM et al (2012) American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol 30:880–887CrossRefPubMed Smith TJ, Temin S, Alesi ER, Abernethy AP, Balboni TA, Basch EM et al (2012) American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol 30:880–887CrossRefPubMed
11.
Zurück zum Zitat Zhang B (2012) Nilsson ME, Prigerson HG: factors important to patients’ quality of life at the end of life. Arch Intern Med 172:1133–1142PubMedCentralPubMed Zhang B (2012) Nilsson ME, Prigerson HG: factors important to patients’ quality of life at the end of life. Arch Intern Med 172:1133–1142PubMedCentralPubMed
12.
Zurück zum Zitat Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139CrossRefPubMed Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139CrossRefPubMed
13.
Zurück zum Zitat Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500CrossRefPubMed Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500CrossRefPubMed
Metadaten
Titel
Characteristics of neoplastic cardiac tamponade and prognosis after pericardiocentesis: a single-center study of 113 consecutive cancer patients
verfasst von
Tsugumi Takayama
Yuji Okura
Yoshinobu Okada
Keiichi Honma
Atsushi Nashimoto
Nobuaki Sato
Akira Yokoyama
Tohru Minamino
Publikationsdatum
01.10.2015
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 5/2015
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-015-0794-7

Weitere Artikel der Ausgabe 5/2015

International Journal of Clinical Oncology 5/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.